<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859141</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-QINF-3002</org_study_id>
    <nct_id>NCT03859141</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)</brief_title>
  <official_title>Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6-35 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent&#xD;
      influenza vaccine in healthy children aged 6-35 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes open-labelled phase I and randomized, double-blind, controlled phase III&#xD;
      clinical trial. In the phase I, 20 healthy Chinese children aged 6-35 months were&#xD;
      administered with two doses of QIV (7.5μg/0.25ml). In the phase Ⅲ clinical trial, 2320&#xD;
      children were assigned to QIV group, TIV (B/Victoria) group and TIV (B/Yamagata) group in a&#xD;
      2:1:1 ratio. All vaccines were manufactured by Sinovac Biotech Co., Ltd.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Actual">November 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The phase Ⅰ clinical trial was a single arm.The phase Ⅲ was 3 parallel arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The lower limit of 95% confidence intervals (95%CI) of geometric mean titer (GMT) ratio (experimental group/control group) of hemagglutination inhibition (HI) antibody titer≥2/3.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index, One of the standard to evaluate the experimental vaccine is non-inferior to the control vaccines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The lower limit of 95% CI of the seroconversion rate difference (experimental group-control group)≥-10%.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index, Another standard to evaluate the experimental vaccine is non-inferior to the control vaccines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95%CI of the ratio of GMT (experimental group/control group) &gt;1.5.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index, One of the standard to evaluate the experimental vaccine is superior to the control vaccines for specific antigen type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95% CI of the difference of HI antibody seroconversion rate (experimental group-control group)&gt;10%</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index, Another standard to evaluate the experimental vaccine is superior to the control vaccines for specific antigen type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95% CI of seroconversion rate for each HI antibody after two doses immunization≥40%.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seroprotective rate (HI antibody titer≥1:40) of each HI antibody after two doses immunization≥70%.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean increase (GMI) of each HI antibody after two doses immunization &gt;2.5.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95%CI of the ratio of GMT(experimental group/control group)≥2/3, in the subjects whose pre-immune HI antibody titer&lt;1:40</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95% CI of the difference of HI antibody seroconversion rate (experimental group-control group)≥-10%, in the subjects whose pre-immune HI antibody titer&lt;1:40.</measure>
    <time_frame>28 days after two doses immunization</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the solicited local and general adverse reactions 0-7 days after each immunization.</measure>
    <time_frame>0-7 days</time_frame>
    <description>Safety index, The adverse reactions refers to the adverse events which were considered related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the unsolicited adverse events 0-28 days after each immunization</measure>
    <time_frame>0-28 days after each dose immunization</time_frame>
    <description>Safety Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the serious adverse events within 7 months after the first immunization.</measure>
    <time_frame>Within 7 months after the first dose immunization</time_frame>
    <description>Safety Index</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2340</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>Experimental group-phase Ⅰ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group-phase Ⅲ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 1-phase Ⅲ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trivalent influenza vaccine (contains B/Victoria strain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2-phase Ⅲ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trivalent influenza vaccine (contains B/Yamagata strain)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent influenza vaccine</intervention_name>
    <description>One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.</description>
    <arm_group_label>Experimental group-phase Ⅰ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent influenza vaccine</intervention_name>
    <description>One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.</description>
    <arm_group_label>Experimental group-phase Ⅲ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine (contains B/Victoria strain)</intervention_name>
    <description>One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.</description>
    <arm_group_label>Control group 1-phase Ⅲ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine (contains B/Yamagata strain)</intervention_name>
    <description>One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.</description>
    <arm_group_label>Control group 2-phase Ⅲ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer between 6 - 35 months old; Term birth; Birth weight &gt;2500g;&#xD;
&#xD;
          -  Proven legal identity;&#xD;
&#xD;
          -  Written consent of the guardian(s) of the volunteer;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received seasonal influenza vaccine in the current year;&#xD;
&#xD;
          -  Suffering from seasonal influenza in the past 6 moths;&#xD;
&#xD;
          -  Axillaty temperature &gt; 37.0 °C;&#xD;
&#xD;
          -  History of allergy to any vaccine or vaccine ingredient;&#xD;
&#xD;
          -  History of serious adverse reaction(s) to vaccination, such as urticaria, difficulty&#xD;
             in breathing, angioneurotic edema, abdominal pain, etc;&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency;&#xD;
&#xD;
          -  Congenital malformation, developmental disorders;&#xD;
&#xD;
          -  Severe malnutrition;&#xD;
&#xD;
          -  Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency,&#xD;
             coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation&#xD;
             disorders;&#xD;
&#xD;
          -  History of epilepsy (except febrile seizures occurred &lt; 2 years of age or pure&#xD;
             epilepsy occurred within the past 3 years that does not need treatment)&#xD;
&#xD;
          -  Chronic diseases (e.g., viral hepatitis, tuberculosis, diabetes, blood diseases, or&#xD;
             neurological disorders)&#xD;
&#xD;
          -  Acute disease or acute stage of chronic disease;&#xD;
&#xD;
          -  Receipt of any of the following products:&#xD;
&#xD;
               1. Any subunit vaccine or inactivated vaccine (e.g., pneumococcal vaccine) or&#xD;
                  treatment of allergy within 14 days prior to study entry;&#xD;
&#xD;
               2. Any live attenuated vaccine within 30 days prior to study entry;&#xD;
&#xD;
               3. Any other investigational medicine(s) or vaccine within 30 days prior to study&#xD;
                  entry;&#xD;
&#xD;
               4. Blood product within 3 months prior to study entry;&#xD;
&#xD;
               5. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except&#xD;
                  corticosteroid spray for treatment of allergic rhinitis or corticosteroid&#xD;
                  treatment on surface for acute non-complicated dermatitis) within 6 month prior&#xD;
                  to study entry;&#xD;
&#xD;
          -  Participate or will participate in other clinical trial(s) during this study;&#xD;
&#xD;
          -  Based on the judgment of investigator(s) or the Ethic Committee, there was any&#xD;
             condition indicating that the subject should be excluded;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuemei Hu, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guanyun Center for Disease Prevention and Control</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pizhou Center for Disease Prevention and Control</name>
      <address>
        <city>Pizhou</city>
        <state>Jiangsu</state>
        <zip>221300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccine</keyword>
  <keyword>Quadrivalent</keyword>
  <keyword>Trivalent</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

